Abstract 140P
Background
Periampullary carcinoma accounts for over 30,000 cancer-related deaths per year in the US. The outcome of the disease differs according to the chosen modality of treatment. This study compared the survival rate between patients undergoing pancreaticoduodenectomy alone versus those receiving neoadjuvant chemotherapy before undergoing the surgery in stage II and III periampullary carcinoma.
Methods
Using the SEER database, we extracted the data of 868 patients with periampullary carcinoma from 2007 to 2011, aged between 40-79 years old. We selected patients with periampullary carcinomas who underwent pancreaticoduodenectomy alone compared to those received neoadjuvant chemotherapy before the surgery.
Results
The highest 5-year survival rate was observed in patients receiving neoadjuvant chemotherapy followed by pancreaticoduodenectomy (20.1%); especially those of stage II (20.1%). However, we found no significant difference in overall survival regarding the patients' gender or race.Table:
140P
Variables | Overall survival | p-value |
---|---|---|
Therapy Surgery Combined | 17.3% 20.1% | 0.000** |
Stage II III | 20.1% 7.9 % | 0.000** |
Race White Black | 19.0% 22.7% | 0.732 |
Sex Male Female | 19.3% 19.5% | 0.388 |
Highly significant p-value at ≤ 0.001 Combined: neoadjuvant chemotherapy and surgery.
Conclusions
Patients receiving neoadjuvant chemotherapy before pancreaticoduodenectomy had better 5-year overall survival compared to those undergoing pancreaticoduodenectomy alone; especially stage II.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mai Abdelkader.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract